168 related articles for article (PubMed ID: 34767925)
1. Patient-derived xenograft models of neuroendocrine prostate cancer.
Shi M; Wang Y; Lin D; Wang Y
Cancer Lett; 2022 Jan; 525():160-169. PubMed ID: 34767925
[TBL] [Abstract][Full Text] [Related]
2. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract][Full Text] [Related]
3. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
4. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract][Full Text] [Related]
5. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
Anselmino N; Labanca E; Shepherd PDA; Dong J; Yang J; Song X; Nandakumar S; Kundra R; Lee C; Schultz N; Zhang J; Araujo JC; Aparicio AM; Subudhi SK; Corn PG; Pisters LL; Ward JF; Davis JW; Vazquez ES; Gueron G; Logothetis CJ; Futreal A; Troncoso P; Chen Y; Navone NM
Clin Cancer Res; 2024 May; 30(10):2272-2285. PubMed ID: 38488813
[TBL] [Abstract][Full Text] [Related]
6. LIN28B promotes the development of neuroendocrine prostate cancer.
Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
[TBL] [Abstract][Full Text] [Related]
8. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
Lee AR; Li Y; Xie N; Gleave ME; Cox ME; Collins CC; Dong X
Oncotarget; 2017 Apr; 8(17):27966-27975. PubMed ID: 28427194
[TBL] [Abstract][Full Text] [Related]
9. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Beshiri ML; Tice CM; Tran C; Nguyen HM; Sowalsky AG; Agarwal S; Jansson KH; Yang Q; McGowen KM; Yin J; Alilin AN; Karzai FH; Dahut WL; Corey E; Kelly K
Clin Cancer Res; 2018 Sep; 24(17):4332-4345. PubMed ID: 29748182
[No Abstract] [Full Text] [Related]
10. Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.
Ci X; Hao J; Dong X; Xue H; Wu R; Choi SYC; Haegert AM; Collins CC; Liu X; Lin D; Wang Y
Cells; 2020 Jun; 9(6):. PubMed ID: 32512818
[TBL] [Abstract][Full Text] [Related]
11. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L; Sabio J; Poiraudeau L; Annereau M; Menssouri N; Helissey C; Déas O; Aglave M; Ibrahim T; Pobel C; Nobre C; Nicotra C; Ngo-Camus M; Lacroix L; Rouleau E; Tselikas L; Judde JG; Chauchereau A; Bernard-Tessier A; Patrikidou A; Naoun N; Flippot R; Colomba E; Fuerea A; Albiges L; Lavaud P; Massard C; Friboulet L; Fizazi K; Besse B; Scoazec JY; Loriot Y
Eur Urol Oncol; 2024 Jun; 7(3):527-536. PubMed ID: 38433714
[TBL] [Abstract][Full Text] [Related]
12. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
[TBL] [Abstract][Full Text] [Related]
13. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
Risbridger GP; Clark AK; Porter LH; Toivanen R; Bakshi A; Lister NL; Pook D; Pezaro CJ; Sandhu S; Keerthikumar S; Quezada Urban R; Papargiris M; Kraska J; Madsen HB; Wang H; Richards MG; Niranjan B; O'Dea S; Teng L; Wheelahan W; Li Z; Choo N; Ouyang JF; Thorne H; Devereux L; Hicks RJ; Sengupta S; Harewood L; Iddawala M; Azad AA; Goad J; Grummet J; Kourambas J; Kwan EM; Moon D; Murphy DG; Pedersen J; Clouston D; Norden S; Ryan A; Furic L; Goode DL; Frydenberg M; Lawrence MG; Taylor RA
Nat Commun; 2021 Aug; 12(1):5049. PubMed ID: 34413304
[TBL] [Abstract][Full Text] [Related]
14. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.
Porter LH; Lawrence MG; Wang H; Clark AK; Bakshi A; Obinata D; Goode D; Papargiris M; Mural ; Clouston D; Ryan A; Norden S; Corey E; Nelson PS; Isaacs JT; Grummet J; Kourambas J; Sandhu S; Murphy DG; Pook D; Frydenberg M; Taylor RA; Risbridger GP
Prostate; 2019 Aug; 79(11):1326-1337. PubMed ID: 31212368
[TBL] [Abstract][Full Text] [Related]
15. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ
Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054
[TBL] [Abstract][Full Text] [Related]
16. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
[TBL] [Abstract][Full Text] [Related]
17. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
18. Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.
Lam HM; Nguyen HM; Corey E
Methods Mol Biol; 2018; 1786():1-27. PubMed ID: 29786784
[TBL] [Abstract][Full Text] [Related]
19. ONECUT2 is a driver of neuroendocrine prostate cancer.
Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
